Hyperfine, Inc. (NASDAQ:HYPR) Stock Has Average Price Target of $2.02

Key Points

• Analysts have a “Moderate Buy” consensus on Hyperfine, with three buy ratings, one strong-buy, one hold and one sell. The average 12-month price target is $2.02, versus a recent share price of $0.72.
• Hyperfine reported quarterly revenue of $3.90 million, below the $4.13 million analyst estimate, while its adjusted loss of $0.09 per share matched expectations. Analysts expect a full-year loss of approximately $0.34 per share.
• Institutional investors and hedge funds own 15.03% of the company, with several funds increasing their positions. Hyperfine develops portable, low-field MRI systems, including its bedside Swoop Portable MR Imaging System.

Hyperfine, Inc. (NASDAQ:HYPR - Get Free Report) has been given an average recommendation of "Moderate Buy" by the six research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $2.02.

A number of equities research analysts have issued reports on HYPR shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of Hyperfine in a report on Thursday, October 15th. Lucid Cap Mkts assumed coverage on Hyperfine in a research report on Tuesday, October 27th. They set a "strong-buy" rating on the stock. BTIG Research reaffirmed a "buy" rating and set a $2.00 price objective on shares of Hyperfine in a research report on Tuesday, September 22nd. Wall Street Zen cut Hyperfine from a "hold" rating to a "sell" rating in a research note on Saturday. Finally, Loop Capital set a $2.00 target price on Hyperfine in a report on Tuesday.

Institutional Investors Weigh In On Hyperfine

A number of hedge funds have recently bought and sold shares of HYPR. Renaissance Technologies LLC increased its stake in shares of Hyperfine by 100.2% during the first quarter. Renaissance Technologies LLC now owns 730,233 shares of the company's stock worth $789,000 after buying an additional 365,490 shares during the period. Bank of New York Mellon Corp acquired a new stake in Hyperfine in the second quarter valued at approximately $419,000. Walleye Capital LLC raised its holdings in Hyperfine by 3.4% in the first quarter. Walleye Capital LLC now owns 223,988 shares of the company's stock valued at $242,000 after acquiring an additional 7,330 shares in the last quarter. Finally, PFS Partners LLC lifted its stake in Hyperfine by 150.0% in the third quarter. PFS Partners LLC now owns 50,000 shares of the company's stock worth $40,000 after acquiring an additional 30,000 shares during the last quarter. Institutional investors and hedge funds own 15.03% of the company's stock.

Hyperfine Stock Performance

NASDAQ HYPR opened at $0.72 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 6.15 and a quick ratio of 5.45. The company has a market cap of $76.36 million, a P/E ratio of -1.89 and a beta of 1.45. The stock has a 50-day moving average of $0.81 and a two-hundred day moving average of $1.12. Hyperfine has a 1-year low of $0.70 and a 1-year high of $1.94.

Hyperfine (NASDAQ:HYPR - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.09) EPS for the quarter, meeting the consensus estimate of ($0.09). The business had revenue of $3.90 million during the quarter, compared to analyst estimates of $4.13 million. Hyperfine had a negative net margin of 210.75% and a negative return on equity of 97.88%. As a group, analysts anticipate that Hyperfine will post -0.34 EPS for the current year.

Hyperfine Company Profile

Hyperfine, Inc NASDAQ: HYPR is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings.

Hyperfine's primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient's bedside.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.